Trials / Completed
CompletedNCT04024332
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
A Single-center, Open-label, Single-dose Study to Investigate the Pharmacokinetics of ACT-541468 in Subjects With Severe Renal Impairment Compared to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Study of the way the body takes up, distributes, and gets rid of ACT-541468 in subjects with abnormal kidney function compared to healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-541468 | ACT-541468 25 mg; administered orally |
Timeline
- Start date
- 2019-09-24
- Primary completion
- 2020-08-14
- Completion
- 2020-08-14
- First posted
- 2019-07-18
- Last updated
- 2020-09-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04024332. Inclusion in this directory is not an endorsement.